FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996429159> ?p ?o ?g. }

• W1996429159 endingPage "S75" @default.
• W1996429159 startingPage "S75" @default.
• W1996429159 abstract "Five hundred and twenty-one patients with ABC were randomized to receive PTX over 3-hr or 24-hr q 3 wks at an initial dose of 175 mg/m2 (with escalation when possible). The pre-randomization strata were defined according to prior chemotherapy (CT): none, adjuvant CT only, CT for ABC. Two-thirds of the patients had prior anthracycline exposure; 24% of these were anthracycline resistant, i.e. progressing on or relapsing within 6 months of an anthracycline regimen. The response rate was 29% in the 3-hr vs 32% in the 24-hr (P = 0.629). It was 28% in both arms among anthracycline pretreated patients. Among all patients, treatment over 24-hr resulted in a longer time to progression (TTP) (median 3.8 mos vs 4.6 mos: P = 0.021) and survival time (median 9.8 mosvs 13.4 mos; P = 0.021). This difference was not apparent after adjustment for prognostic factors, TTP: P = 0.081, survival: P = 0.099. Treatment was well tolerated as documented by the # of crs administered (median 6 (1–22+) vs 7 (1–21); P < 0.01). More patients in the 3-hr arm had their PTX dose escalated (65% in the 3-hr vs 33% in the 24-hr. P < 0.001), resulting in an increased dose intensity (62 vs 57 mg/m2/wk; P < 0.001). The 2 treatment schedules were not equitoxic even after individual dose adjustments. The 24-hr infusion resulted in more severe hematologic (30% vs 79% grade IV neutropenia, P < 0.001; 1% vs 17% febrile neutropenia, P < 0.001), and GI toxicity (22% vs 45% mucositis, P < 0.001; 25% vs 41% diarrhea, P < 0.001). The 3-hr infusion with its higher dose intensity resulted in a higher incidence of peripheral neuropathy (78% vs 65%, P = 0.001). To evaluate the risk-benefit ratio associated with therapy, we retrospectively analyze the time to either progression or to clinically important adverse events (febrile neutropenia, severe hypersensitivity reaction, and severe neuropathy), and found no statistically significant difference between the two arms (median 3.3 mos vs 3.4 mos; P = 0.243). In the palliative setting, the 24-hr infusion of PTX had some efficacy advantage, but did not result in a significant increase in patient benefit as compared to the 3-hr infusion. This trial confirms the activity of PTX in the treatment of ABC pts, including anthracycline pretreated patients. Five hundred and twenty-one patients with ABC were randomized to receive PTX over 3-hr or 24-hr q 3 wks at an initial dose of 175 mg/m2 (with escalation when possible). The pre-randomization strata were defined according to prior chemotherapy (CT): none, adjuvant CT only, CT for ABC. Two-thirds of the patients had prior anthracycline exposure; 24% of these were anthracycline resistant, i.e. progressing on or relapsing within 6 months of an anthracycline regimen. The response rate was 29% in the 3-hr vs 32% in the 24-hr (P = 0.629). It was 28% in both arms among anthracycline pretreated patients. Among all patients, treatment over 24-hr resulted in a longer time to progression (TTP) (median 3.8 mos vs 4.6 mos: P = 0.021) and survival time (median 9.8 mosvs 13.4 mos; P = 0.021). This difference was not apparent after adjustment for prognostic factors, TTP: P = 0.081, survival: P = 0.099. Treatment was well tolerated as documented by the # of crs administered (median 6 (1–22+) vs 7 (1–21); P < 0.01). More patients in the 3-hr arm had their PTX dose escalated (65% in the 3-hr vs 33% in the 24-hr. P < 0.001), resulting in an increased dose intensity (62 vs 57 mg/m2/wk; P < 0.001). The 2 treatment schedules were not equitoxic even after individual dose adjustments. The 24-hr infusion resulted in more severe hematologic (30% vs 79% grade IV neutropenia, P < 0.001; 1% vs 17% febrile neutropenia, P < 0.001), and GI toxicity (22% vs 45% mucositis, P < 0.001; 25% vs 41% diarrhea, P < 0.001). The 3-hr infusion with its higher dose intensity resulted in a higher incidence of peripheral neuropathy (78% vs 65%, P = 0.001). To evaluate the risk-benefit ratio associated with therapy, we retrospectively analyze the time to either progression or to clinically important adverse events (febrile neutropenia, severe hypersensitivity reaction, and severe neuropathy), and found no statistically significant difference between the two arms (median 3.3 mos vs 3.4 mos; P = 0.243). In the palliative setting, the 24-hr infusion of PTX had some efficacy advantage, but did not result in a significant increase in patient benefit as compared to the 3-hr infusion. This trial confirms the activity of PTX in the treatment of ABC pts, including anthracycline pretreated patients." @default.
• W1996429159 created "2016-06-24" @default.
• W1996429159 creator A5001188276 @default.
• W1996429159 creator A5005207507 @default.
• W1996429159 creator A5006226592 @default.
• W1996429159 creator A5009729018 @default.
• W1996429159 creator A5014711481 @default.
• W1996429159 creator A5016647351 @default.
• W1996429159 creator A5016706537 @default.
• W1996429159 creator A5020560009 @default.
• W1996429159 creator A5021515904 @default.
• W1996429159 creator A5028943009 @default.
• W1996429159 creator A5032321264 @default.
• W1996429159 creator A5034122494 @default.
• W1996429159 creator A5041209157 @default.
• W1996429159 creator A5042880619 @default.
• W1996429159 creator A5047164121 @default.
• W1996429159 creator A5062283775 @default.
• W1996429159 creator A5063935752 @default.
• W1996429159 creator A5064417270 @default.
• W1996429159 creator A5067468792 @default.
• W1996429159 creator A5075618091 @default.
• W1996429159 creator A5077166346 @default.
• W1996429159 creator A5077857574 @default.
• W1996429159 creator A5087442048 @default.
• W1996429159 creator A5087662577 @default.
• W1996429159 date "1995-11-01" @default.
• W1996429159 modified "2023-09-27" @default.
• W1996429159 title "345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)" @default.
• W1996429159 doi "https://doi.org/10.1016/0959-8049(95)95598-z" @default.
• W1996429159 hasPublicationYear "1995" @default.
• W1996429159 type Work @default.
• W1996429159 sameAs 1996429159 @default.
• W1996429159 citedByCount "33" @default.
• W1996429159 countsByYear W19964291592019 @default.
• W1996429159 crossrefType "journal-article" @default.
• W1996429159 hasAuthorship W1996429159A5001188276 @default.
• W1996429159 hasAuthorship W1996429159A5005207507 @default.
• W1996429159 hasAuthorship W1996429159A5006226592 @default.
• W1996429159 hasAuthorship W1996429159A5009729018 @default.
• W1996429159 hasAuthorship W1996429159A5014711481 @default.
• W1996429159 hasAuthorship W1996429159A5016647351 @default.
• W1996429159 hasAuthorship W1996429159A5016706537 @default.
• W1996429159 hasAuthorship W1996429159A5020560009 @default.
• W1996429159 hasAuthorship W1996429159A5021515904 @default.
• W1996429159 hasAuthorship W1996429159A5028943009 @default.
• W1996429159 hasAuthorship W1996429159A5032321264 @default.
• W1996429159 hasAuthorship W1996429159A5034122494 @default.
• W1996429159 hasAuthorship W1996429159A5041209157 @default.
• W1996429159 hasAuthorship W1996429159A5042880619 @default.
• W1996429159 hasAuthorship W1996429159A5047164121 @default.
• W1996429159 hasAuthorship W1996429159A5062283775 @default.
• W1996429159 hasAuthorship W1996429159A5063935752 @default.
• W1996429159 hasAuthorship W1996429159A5064417270 @default.
• W1996429159 hasAuthorship W1996429159A5067468792 @default.
• W1996429159 hasAuthorship W1996429159A5075618091 @default.
• W1996429159 hasAuthorship W1996429159A5077166346 @default.
• W1996429159 hasAuthorship W1996429159A5077857574 @default.
• W1996429159 hasAuthorship W1996429159A5087442048 @default.
• W1996429159 hasAuthorship W1996429159A5087662577 @default.
• W1996429159 hasConcept C121608353 @default.
• W1996429159 hasConcept C126322002 @default.
• W1996429159 hasConcept C141071460 @default.
• W1996429159 hasConcept C168563851 @default.
• W1996429159 hasConcept C204243189 @default.
• W1996429159 hasConcept C2776694085 @default.
• W1996429159 hasConcept C2776802502 @default.
• W1996429159 hasConcept C2777063308 @default.
• W1996429159 hasConcept C2777292972 @default.
• W1996429159 hasConcept C2777511904 @default.
• W1996429159 hasConcept C2777863537 @default.
• W1996429159 hasConcept C2781413609 @default.
• W1996429159 hasConcept C530470458 @default.
• W1996429159 hasConcept C71924100 @default.
• W1996429159 hasConcept C90924648 @default.
• W1996429159 hasConceptScore W1996429159C121608353 @default.
• W1996429159 hasConceptScore W1996429159C126322002 @default.
• W1996429159 hasConceptScore W1996429159C141071460 @default.
• W1996429159 hasConceptScore W1996429159C168563851 @default.
• W1996429159 hasConceptScore W1996429159C204243189 @default.
• W1996429159 hasConceptScore W1996429159C2776694085 @default.
• W1996429159 hasConceptScore W1996429159C2776802502 @default.
• W1996429159 hasConceptScore W1996429159C2777063308 @default.
• W1996429159 hasConceptScore W1996429159C2777292972 @default.
• W1996429159 hasConceptScore W1996429159C2777511904 @default.
• W1996429159 hasConceptScore W1996429159C2777863537 @default.
• W1996429159 hasConceptScore W1996429159C2781413609 @default.
• W1996429159 hasConceptScore W1996429159C530470458 @default.
• W1996429159 hasConceptScore W1996429159C71924100 @default.
• W1996429159 hasConceptScore W1996429159C90924648 @default.
• W1996429159 hasLocation W19964291591 @default.
• W1996429159 hasOpenAccess W1996429159 @default.
• W1996429159 hasPrimaryLocation W19964291591 @default.
• W1996429159 hasRelatedWork W193631302 @default.
• W1996429159 hasRelatedWork W2020150632 @default.
• W1996429159 hasRelatedWork W2062226191 @default.
• W1996429159 hasRelatedWork W2063667079 @default.
• W1996429159 hasRelatedWork W2383272827 @default.

• next